Legend Biotech (LEGN) announces the appointment of Carlos Santos as the Company’s Chief Financial Officer, effective immediately. Santos assumes the role from Jessie Yeung, who has served as the interim CFO since January 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LEGN:
- Legend Biotech’s Earnings Call: Growth and Success
- Legend Biotech price target raised to $77 from $75 at RBC Capital
- Positive Outlook for Legend Biotech: Strong Sales Growth and Strategic Advancements Drive Buy Rating
- Legend Biotech’s Strategic Growth and Record Sales Drive Buy Rating
- Strong Buy Rating for Legend Biotech Driven by CARVYKTI’s Market Success and Strategic Expansions